Mid-cap Health Care company Exelixis has logged a -0.2% change today on a trading volume of 711,112. The average volume for the stock is 2,449,162.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Based in Alameda, United States the company has 1,223 full time employees and a market cap of $6,408,536,064.
The company is now trading -21.06% away from its average analyst target price of $24.93 per share. The 15 analysts following the stock have set target prices ranging from $17.0 to $32.0, and on average give Exelixis a rating of buy.
Over the last 12 months EXEL shares have declined by -828.3%, which represents a difference of -2045.0% when compared to the S&P 500. The stock's 52 week high is $22.04 per share and its 52 week low is $14.87. With its net margins declining an average -23.6% over the last 4 years, Exelixis declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-07 | 1,611,062 | 182,282 | 11.31 | -29.75 |
| 2022-02-18 | 1,434,970 | 231,063 | 16.1 | 42.23 |
| 2021-02-11 | 987,538 | 111,781 | 11.32 | -65.87 |
| 2020-02-25 | 967,775 | 321,012 | 33.17 | n/a |
